Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of pirfenidone

A technology for the use of pirfenidone, applied in the field of new uses of pirfenidone, can solve the problem of high price, achieve good activity, obvious therapeutic effect, and the effect of inhibiting choroidal angiogenesis

Inactive Publication Date: 2014-05-21
张康
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because Lucentis is an antibody drug and its price is extremely high, it cannot be popularized all over the world
There is no report on the use of pirfenidone to inhibit angiogenesis and treat wet macular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of pirfenidone
  • Novel application of pirfenidone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Effect of pirfenidone on choroidal neovascularization

[0022] Laser-induced choroidal neovascularization (Choroidal Neovascularization, CNV) animal model was used for experiments. This model is currently the most widely used animal model used to study the effect of drugs on the formation of CNV, that is, the disease model of wet macular degeneration [Jiang Wei, et al. Research progress in age-related macular degeneration (AMD) experimental models. International Journal of Ophthalmology, 2007(3):585-589].

[0023] 1. The effect of intravitreal injection of pirfenidone on laser-induced CNV

[0024] According to the pre-test, the final concentration of pirfenidone in the vitreous is planned to be 2mM (0.37mg / ml). Therefore, the pirfenidone solution is prepared with phosphate buffered saline (PBS) pH=7.0-7.2, and the concentration of pirfenidone is observed. Whether fenidone can inhibit the formation of experimental CNV.

[0025] CNV formation induced by laser...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides application of pirfenidone in preparing anti-angiogenesis medicines, and provides a medicine for treating wet macular degeneration. Pirfenidone can be used for effectively inhibiting choroid angiogenesis, has an excellent activity by eye dropping and intraocular injection, can be used for treatment of angiogenesis diseases in ophthalmological department, in particular remarkable treatment effect to wet macular degeneration, and provides a novel choice for clinical administration.

Description

technical field [0001] The invention relates to a new application of pirfenidone and a new dosage form of pirfenidone. Background technique [0002] Angiogenesis is the process of sprouting new blood vessels from existing blood vessels. This process is associated with migration and proliferation of vascular endothelial cells. Angiogenesis is related to many major human diseases, such as malignant tumors. At present, it has been found that ocular angiogenesis diseases, including age-related macular degeneration (AMD), diabetic retinopathy, neovascular glaucoma, etc., are all characterized by abnormal proliferation of ocular neovascularization (Jin Xiao, et al. , Research progress on the application and mechanism of anti-VEGF drugs in ophthalmic diseases, Zhongwai Medical, 2012). [0003] Among them, there are mainly two types of macular degeneration: dry and wet. Wet macular degeneration (AMD) is characterized by new blood vessels in the choroid entering under the retina a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4418A61P27/02A61P9/10
Inventor 张康
Owner 张康
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com